Compare Marvell Technology Inc (MRVL) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs 22nd Century Group Inc — how do they compare? Marvell Technology Inc trades at $274.74 (market cap $246.84B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Marvell Technology Inc is far larger — about 397059.5× 22nd Century Group Inc's market cap, and Marvell Technology Inc pays a 0.09% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and 22nd Century Group Inc for 32 Days on average.
| MRVL | XXII | |
|---|---|---|
Market Cap | $246.84B | $621.67K |
Volume | 29,003,830 | 45,625 |
Sector | Technology | Consumer Staples |
52-Week High | $316.43 | $483.00 |
52-Week Low | $73.73 | $0.80 |
Typical Hold Time | 42 Days | 32 Days |
Enterprise Value | $248.19B | -$3.69M |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $275.28, down 3.3% in the last session, but maintains strong technical momentum with bullish moving averages and support at $267. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS expected at $1.1. Revenue growth accelerated to 42% in fiscal 2026, driven by data center products comprising 74% of sales. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $327.86 price target, representing 19% upside potential.
Marvell's AI-driven growth story appears compelling with custom chip deals with hyperscalers potentially generating $120 billion in cumulative revenue. However, high valuation multiples (P/E 90.95, P/S 25.77) and recent net losses (-$885M in 2025) present risks. The stock's 210% YTD gain suggests much optimism is priced in, requiring continued execution on the $18 billion fiscal 2028 revenue guidance to justify current levels.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
